Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryClinical TrialCRO

PUBLISHER: Grand View Research | PRODUCT CODE: 1446532

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1446532

India Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Toxicology Testing), By Model Type, By End-use (Biopharmaceutical Companies, Government & Academic Institutes), And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 80 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

India Preclinical CRO Market Growth & Trends:

The India preclinical CRO market is anticipated to reach USD 393.6 million by 2030 and is projected to grow at a CAGR of 11.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The factors driving the growth are multifaceted, encompassing cost advantages, a skilled workforce, increasing outsourcing trends and R&D of clinical trials worldwide. According to a study on the CRO sector in India in August 2023 by the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers Government of India, the aggregate R&D expenditure of the largest pharmaceutical corporations in 2022 exceeded USD 138 billion, up 1.7% from 2021.

The market growth is fueled by the rising trend of global outsourcing of research and development (R&D) functions. Industries such as pharmaceuticals, biotechnology, medical devices, and agrochemicals are leveraging the capabilities of CROs to carry out preclinical research studies. This allows pharmaceutical companies to delegate certain aspects of their R&D while focusing on their core competencies.

Advanced technologies such as high-throughput screening, silicon modeling, and advanced imaging have boosted preclinical CROs in India by speeding up drug discovery and development, making them faster and more accurate. Automation and robotics have also increased efficiency and reduced experiment turnaround times. India's large patient population, network of hospitals, and cost-effective operations with skilled human resources are expected to drive the market's growth.

India Preclinical CRO Market Report Highlights:

  • Based on services, the toxicology testing segment led the market with a largest revenue share of 22.5% in 2023, owing to rising rate of outsourcing of non-core preclinical CRO research
  • Based on service, the bioanalysis and DMPK studies segment is expected to grow at the fastest CAGR over the forecast period, due to technological developmentsin analytical techniques, increased R&D in the pharmaceutical sector, and theshift to personalized medicine
  • Based on model types, the patient derived organoid (PDOs) models segment held the market with the largest revenue share of 80.6% in 2023, and is anticipated to witness the fastest CAGR during the forecast period, owing to theshift to personalized medicine, its use in drug development and disease modeling
  • Based on end-use, the biopharmaceutical companies segment held the market with largest revenue share of 85.0% in 2023, due to cost-effectiveness, access to advanced technologies, expertise, faster timelines, risk mitigation, and the ability to focus on core competencies
  • In May 2023, Aragen Life Sciences Ltd. and Far Biotech announced a partnership to advance preclinical initiatives in the field of neurodegeneration. Aragen will utilize its experimental discovery platform to help FAR Biotech reach an essential milestone in neurodegeneration with its small molecule program
Show more
Product Code: GVR-4-68040-198-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Service
    • 1.2.2. Model type
    • 1.2.3. End use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Service outlook
    • 2.2.2. Model type outlook
    • 2.2.3. Application outlook
  • 2.3. Competitive Insights

Chapter 3. India Preclinical CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. India Preclinical CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Legal landscape
      • 3.3.2.6. Environmental landscape

Chapter 4. India Preclinical CRO Market: Service Estimates & Trend Analysis

  • 4.1. Service Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. India Preclinical CRO Market by Service Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
    • 4.4.1. Service
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1. Bioanalysis and DMPK studies
      • 4.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1.1.1. In vitro ADME
      • 4.4.1.1.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1.1.2. In-vivo PK
      • 4.4.1.1.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.2. Toxicology testing
      • 4.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.2.1.1. GLP
      • 4.4.1.1.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.2.1.2. Non-GLP
      • 4.4.1.1.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.3. Compound management
      • 4.4.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.3.1.1. Process R&D
      • 4.4.1.1.3.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.3.1.2. Custom synthesis
      • 4.4.1.1.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.3.1.3. Others
      • 4.4.1.1.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.4. Chemistry
      • 4.4.1.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.4.1.1. Medicinal chemistry
      • 4.4.1.1.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.4.1.2. Computation chemistry
      • 4.4.1.1.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.5. Safety pharmacology
      • 4.4.1.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.6. Others
      • 4.4.1.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Model type
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.1. Patient Derived Organoid (PDO) model
      • 4.4.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.2. Patient derived xenograft model
      • 4.4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. End use
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.1.1. Biopharmaceutical companies
      • 4.4.3.1.2. Government and academic institutes
      • 4.4.3.1.3. Medical device companies

Chapter 5. India Preclinical CRO Market: Model Type Estimates & Trend Analysis

  • 5.1. Model Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. India Preclinical CRO Market by Model Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
    • 5.4.1. Patient Derived Organoid (PDO) model
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Patient derived xenograft model
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. India Preclinical CRO Market: End Use Estimates & Trend Analysis

  • 6.1. End use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. India Preclinical CRO Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 For The Following
    • 6.4.1. Biopharmaceutical companies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Government and academic institutes
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Medical device companies
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Syngene International Limited
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Dabur Research
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. JSS Medical Research
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Jubilant Biosys Ltd.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Sugen Life Sciences
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Eurofins Advinus
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. GVRP
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Veeda Clinical Research Limited
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Axis Clinicals
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Syneos Health
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. Ethicare-cro
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives
    • 7.4.12. Liveon Biolabs Pvt.Ltd.
      • 7.4.12.1. Company overview
      • 7.4.12.2. Financial performance
      • 7.4.12.3. Product benchmarking
      • 7.4.12.4. Strategic initiatives
    • 7.4.13. IQVIA Inc
      • 7.4.13.1. Company overview
      • 7.4.13.2. Financial performance
      • 7.4.13.3. Product benchmarking
      • 7.4.13.4. Strategic initiatives
    • 7.4.14. Bioneeds
      • 7.4.14.1. Company overview
      • 7.4.14.2. Financial performance
      • 7.4.14.3. Product benchmarking
      • 7.4.14.4. Strategic initiatives
    • 7.4.15. TheraIndx Lifesciences Pvt. Ltd.
      • 7.4.15.1. Company overview
      • 7.4.15.2. Financial performance
      • 7.4.15.3. Product benchmarking
      • 7.4.15.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-198-4

List of Tables

  • Table 1 List of abbreviations
  • Table 2 India preclinical CRO market, by service, 2018 - 2030 (USD Million)
  • Table 3 India preclinical CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 4 India preclinical CRO market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 Value-chain-based sizing & forecasting
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 India preclinical CRO market: market outlook
  • Fig. 8 India preclinical CRO competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Industry value chain analysis
  • Fig. 13 India preclinical CRO market driver impact
  • Fig. 14 India preclinical CRO market restraint impact
  • Fig. 15 India preclinical CRO market strategic initiatives analysis
  • Fig. 16 India preclinical CRO market: Service movement analysis
  • Fig. 17 India preclinical CRO market: Service outlook and key takeaways
  • Fig. 18 Bioanalysis and DMPK studies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 In vitro ADME market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 In-vivo PK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Toxicology testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 GLP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Non-GLP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Compound management market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Process R&D market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Custom synthesis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Medicinal chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Computation chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Safety pharmacology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 India preclinical CRO market: Model type movement analysis
  • Fig. 34 India preclinical CRO market: Model type outlook and key takeaways
  • Fig. 35 Patient Derived Organoid (PDO) model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Patient derived xenograft model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 India preclinical CRO market: End use movement analysis
  • Fig. 38 India preclinical CRO market: End use outlook and key takeaways
  • Fig. 39 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Government and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!